https://scholars.lib.ntu.edu.tw/handle/123456789/628059
Title: | Erratum: ‘Corrigendum to “2017 Taiwan lipid guidelines for high risk patients” [Journal of the Formosan Medical Association (2017) [217–248]’(S0929664616304302)(10.1016/j.jfma.2016.11.013) | Authors: | Li, Yi-Heng Ueng, Kwo-Chang JIANN-SHING JENG Charng, Min-Ji TSUNG-HSIEN LIN KUO-LIONG CHIEN CHIH-YUAN WANG Chao, Ting-Hsing Liu, Ping-Yen Su, Cheng-Huang Chien, Shih-Chieh Liou, Chia-Wei SUNG-CHUN TANG Lee, Chun-Chuan Yu, Tse-Ya Chen, Jaw-Wen CHAU-CHUNG WU Yeh, Hung-I |
Issue Date: | Aug-2018 | Publisher: | ELSEVIER TAIWAN | Journal Volume: | 117 | Journal Issue: | 8 | Start page/Pages: | 749 | Source: | Journal of the Formosan Medical Association = Taiwan yi zhi | Abstract: | In the page 225, left column, lines 3–7 of the article cited above, the sentence “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH), and statin-intolerant patients”, should have read “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH; evolocumab only), heterozygous FH, and statin-intolerant patients.” The authors would like to apologize for any inconvenience caused. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/628059 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2018.07.007 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.